Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 571 AL 585

Insights into the Explicit Protective Activity of Herbals in Management of Neurodegenerative and Cerebrovascular Disorders

Behl T, Makkar R, Sehgal A, Sharma N, Singh S, Albratty M, Najmi A, Meraya AM, Bungau SG.

Molecules. 2022 Aug 4;27(15):4970. doi: 10.3390/molecules27154970.

Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders

Khan H, Tiwari C, Grewal AK, Singh TG, Chauhan S, Batiha GE.

Inflammopharmacology. 2022 Dec;30(6):2051-2061. doi: 10.1007/s10787-022-01072-1. Epub 2022 Oct 22.

Alzheimer's Disease as a Major Public Health Concern: Role of Dietary Saponins in Mitigating Neurodegenerative Disorders and Their Underlying Mechanisms

Abduljawad AA, Elawad MA, Elkhalifa MEM, Ahmed A, Hamdoon AAE, Salim LHM, Ashraf M, Ayaz M, Hassan SSU, Bungau S.

Molecules. 2022 Oct 11;27(20):6804. doi: 10.3390/molecules27206804.

The Neuroprotective Potentiality of Flavonoids on Alzheimer's Disease

Calderaro A, Patanè GT, Tellone E, Barreca D, Ficarra S, Misiti F, Laganà G.

Int J Mol Sci. 2022 Nov 27;23(23):14835. doi: 10.3390/ijms232314835.

Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases

Xia X, Wang Y, Zheng JC.

Transl Neurodegener. 2022 Dec 12;11(1):53. doi: 10.1186/s40035-022-00330-0.

Acylhydrazones and Their Biological Activity: A Review

Socea LI, Barbuceanu SF, Pahontu EM, Dumitru AC, Nitulescu GM, Sfetea RC, Apostol TV.

Molecules. 2022 Dec 9;27(24):8719. doi: 10.3390/molecules27248719.

Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders

Hölscher C.

Br J Pharmacol. 2022 Feb;179(4):695-714. doi: 10.1111/bph.15508. Epub 2021 May 29.

Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment

Pathak N, Vimal SK, Tandon I, Agrawal L, Hongyi C, Bhattacharyya S.

Metab Brain Dis. 2022 Jan;37(1):67-104. doi: 10.1007/s11011-021-00800-w. Epub 2021 Nov 1.

Advancements and future directions in research of the roles of insulin in amyloid diseases

Miller Y.

Biophys Chem. 2022 Feb;281:106720. doi: 10.1016/j.bpc.2021.106720. Epub 2021 Nov 17.

A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism

Chen Y, Liu P, Xie F, Wang B, Lin Z, Luo W.

Neurol Sci. 2022 Feb;43(2):1405-1409. doi: 10.1007/s10072-021-05726-w. Epub 2021 Nov 29.

Lewy Body Dementias: Controversies and Drug Development

Chiu SY, Bowers D, Armstrong MJ.

Neurotherapeutics. 2022 Jan;19(1):55-67. doi: 10.1007/s13311-021-01161-z. Epub 2021 Dec 2.

Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial

Biglan K, Munsie L, Svensson KA, Ardayfio P, Pugh M, Sims J, Brys M.

Mov Disord. 2022 Mar;37(3):513-524. doi: 10.1002/mds.28879. Epub 2021 Dec 2.

[Sleep disorders in patients with a neurocognitive disorder]

Moderie C, Carrier J, Dang-Vu TT.

Encephale. 2022 Jun;48(3):325-334. doi: 10.1016/j.encep.2021.08.014. Epub 2021 Dec 14.

Targeting disorders in unstructured and structured proteins in various diseases

Choudhary S, Lopus M, Hosur RV.

Biophys Chem. 2022 Feb;281:106742. doi: 10.1016/j.bpc.2021.106742. Epub 2021 Dec 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias